MTOR and mucoepidermoid carcinoma: Nakano et al.’s work offers preliminary preclinical evidence (on cell lines UM-HNC.3b and UM-HNC-3A), for a novel approach to treating mucoepidermoid carcinoma (MEC), which combines platinum-based cytotoxic therapy (to debulk the tumor) with an mTOR inhibitor (to ablate CSCs) [113].